文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

阿司匹林或利伐沙班用于髋或膝关节置换术后静脉血栓栓塞预防

Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
PubMed 文献 · N Engl J Med · 2018-01-01
一句话结论全髋或全膝关节置换术后先接受5天利伐沙班预防的患者,延长预防换用阿司匹林在预防症状性静脉血栓栓塞方面与继续利伐沙班无显著差异。

这项多中心、双盲、随机对照试验纳入3424例全髋或全膝关节置换患者,所有患者术后先口服利伐沙班10 mg每日一次至术后第5天,随后随机继续利伐沙班或换用阿司匹林81 mg每日一次,全膝关节置换术后再用9天、全髋关节置换术后再用30天,随访90天。症状性静脉血栓栓塞发生率阿司匹林组0.64%(11/1707)与利伐沙班组0.70%(12/1717)无显著差异(差值0.06个百分点,95%CI -0.55至0.66;非劣效P<0.001,优效P=0.84)。大出血阿司匹林组0.47%(8例)与利伐沙班组0.29%(5例)无显著差异(差值0.18个百分点,95%CI -0.65至0.29;P=0.42),临床重要出血阿司匹林组1.29%(22例)与利伐沙班组0.99%(17例)无显著差异(差值0.30个百分点,95%CI -1.07至0.47;P=0.43)。

要点

  • 全髋或全膝关节置换术后已用利伐沙班10 mg每日一次至术后第5天的患者,延长预防换用阿司匹林81 mg每日一次与继续利伐沙班相比,症状性静脉血栓栓塞发生率无显著差异(0.64% vs 0.70%,差值0.06个百分点,95%CI -0.55至0.66)。
  • 大出血发生率阿司匹林组0.47% vs 利伐沙班组0.29%,差值0.18个百分点(95%CI -0.65至0.29,P=0.42),无显著差异。
  • 临床重要出血发生率阿司匹林组1.29% vs 利伐沙班组0.99%,差值0.30个百分点(95%CI -1.07至0.47,P=0.43),无显著差异。
  • 延长预防疗程:全膝关节置换术后额外9天,全髋关节置换术后额外30天,随访90天。
  • 本研究为非劣效设计,症状性静脉血栓栓塞非劣效P<0.001,优效性P=0.84。

适用人群与场景

  • 接受全髋关节置换或全膝关节置换的患者,共3424例(全髋1804例,全膝1620例)。

处置流程与药物剂量

  • 所有患者术后口服利伐沙班10 mg每日一次至术后第5天。
  • 术后第5天后随机继续利伐沙班10 mg每日一次或换用阿司匹林81 mg每日一次,全膝关节置换术后额外9天,全髋关节置换术后额外30天。

研究设计与关键结果

  • 多中心、双盲、随机对照试验,纳入3424例全髋或全膝关节置换患者,比较术后5天利伐沙班后延长预防用阿司匹林81 mg每日一次 vs 继续利伐沙班10 mg每日一次。
  • 主要有效性终点为90天内症状性静脉血栓栓塞:阿司匹林组11/1707(0.64%)vs 利伐沙班组12/1717(0.70%),差值0.06个百分点(95%CI -0.55至0.66),非劣效P<0.001,优效性P=0.84。
  • 主要安全性终点大出血:阿司匹林组8例(0.47%)vs 利伐沙班组5例(0.29%),差值0.18个百分点(95%CI -0.65至0.29),P=0.42。
  • 临床重要出血:阿司匹林组22例(1.29%)vs 利伐沙班组17例(0.99%),差值0.30个百分点(95%CI -1.07至0.47),P=0.43。

证据类型、等级与局限

  • 证据类型:多中心、双盲、随机对照试验。
  • 非劣效设计,症状性静脉血栓栓塞非劣效P<0.001。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于全髋或全膝关节置换术后已接受5天利伐沙班10 mg每日一次预防的患者,延长预防换用阿司匹林81 mg每日一次在预防症状性静脉血栓栓塞方面与继续利伐沙班无显著差异。
  • 延长预防疗程按手术类型:全膝关节置换术后额外9天,全髋关节置换术后额外30天。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Clinical trials and meta-analyses have suggested that aspirin may be effective for the prevention of venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism) after total hip or total knee arthroplasty, but comparisons with direct oral anticoagulants are lacking for prophylaxis beyond hospital discharge.

METHODS: We performed a multicenter, double-blind, randomized, controlled trial involving patients who were undergoing total hip or knee arthroplasty. All the patients received once-daily oral rivaroxaban (10 mg) until postoperative day 5 and then were randomly assigned to continue rivaroxaban or switch to aspirin (81 mg daily) for an additional 9 days after total knee arthroplasty or for 30 days after total hip arthroplasty. Patients were followed for 90 days for symptomatic venous thromboembolism (the primary effectiveness outcome) and bleeding complications, including major or clinically relevant nonmajor bleeding (the primary safety outcome).

RESULTS: A total of 3424 patients (1804 undergoing total hip arthroplasty and 1620 undergoing total knee arthroplasty) were enrolled in the trial. Venous thromboembolism occurred in 11 of 1707 patients (0.64%) in the aspirin group and in 12 of 1717 patients (0.70%) in the rivaroxaban group (difference, 0.06 percentage points; 95% confidence interval [CI], -0.55 to 0.66; P<0.001 for noninferiority and P=0.84 for superiority). Major bleeding complications occurred in 8 patients (0.47%) in the aspirin group and in 5 (0.29%) in the rivaroxaban group (difference, 0.18 percentage points; 95% CI, -0.65 to 0.29; P=0.42). Clinically important bleeding occurred in 22 patients (1.29%) in the aspirin group and in 17 (0.99%) in the rivaroxaban group (difference, 0.30 percentage points; 95% CI, -1.07 to 0.47; P=0.43).

CONCLUSIONS: Among patients who received 5 days of rivaroxaban prophylaxis after total hip or total knee arthroplasty, extended prophylaxis with aspirin was not significantly different from rivaroxaban in the prevention of symptomatic venous thromboembolism. (Funded by the Canadian Institutes of Health Research; ClinicalTrials.gov number, NCT01720108 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. N Engl J Med. 2018. PMID: 29466159. doi:10.1056/NEJMoa1712746

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。